Pfizer Inc. PFE, +0.52% and German partner BioNTech SE BNTX, +2.78% said Friday an in vitro study found that their COVID-19 vaccine neutralizes the two new highly infectious variants that have emerged in the U.K. and South Africa. The results were published on the preprint service bioRxiv and have not yet been peer-reviewed.
" The trial found the sera of 20 participants in the Phase 3 trials neutralized the virus with the mutation as well as they neutralized the virus without the mutation, said the statement."Pfizer, BioNTech, and UTMB are encouraged by these early, in vitro study findings," said the statement, although further research is needed. The vaccine has been granted emergency use authorization in the U.S. and is currently being deployed.
When is the Astra verdict due?
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.